Annovis Bio (NYSE: ANVS) , a late-stage clinical drug platform company, reported fourth quarter and full year 2024 results, highlighting major milest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback